EA200701633A1 - Вакцина на основе вирусоподобных частиц вируса папилломы человека 16 и вируса папилломы человека 18 l1 - Google Patents

Вакцина на основе вирусоподобных частиц вируса папилломы человека 16 и вируса папилломы человека 18 l1

Info

Publication number
EA200701633A1
EA200701633A1 EA200701633A EA200701633A EA200701633A1 EA 200701633 A1 EA200701633 A1 EA 200701633A1 EA 200701633 A EA200701633 A EA 200701633A EA 200701633 A EA200701633 A EA 200701633A EA 200701633 A1 EA200701633 A1 EA 200701633A1
Authority
EA
Eurasian Patent Office
Prior art keywords
virus
human
particles
papile
volus
Prior art date
Application number
EA200701633A
Other languages
English (en)
Russian (ru)
Inventor
Гари Дьюбин
Брюс Иннис
Монсеф Мохаммед Слэйоу
Мартина Энн Сесиль Веттендорфф
Original Assignee
Глаксосмитклайн Байолоджикалс С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксосмитклайн Байолоджикалс С.А. filed Critical Глаксосмитклайн Байолоджикалс С.А.
Publication of EA200701633A1 publication Critical patent/EA200701633A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EA200701633A 2002-12-20 2003-12-18 Вакцина на основе вирусоподобных частиц вируса папилломы человека 16 и вируса папилломы человека 18 l1 EA200701633A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43503502P 2002-12-20 2002-12-20
US49665303P 2003-08-20 2003-08-20

Publications (1)

Publication Number Publication Date
EA200701633A1 true EA200701633A1 (ru) 2007-12-28

Family

ID=32685362

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200500834A EA009179B1 (ru) 2002-12-20 2003-12-18 Вакцина на основе вирусоподобных частиц вируса папилломы человека 16 и вируса папилломы человека 18 l1
EA200701633A EA200701633A1 (ru) 2002-12-20 2003-12-18 Вакцина на основе вирусоподобных частиц вируса папилломы человека 16 и вируса папилломы человека 18 l1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200500834A EA009179B1 (ru) 2002-12-20 2003-12-18 Вакцина на основе вирусоподобных частиц вируса папилломы человека 16 и вируса папилломы человека 18 l1

Country Status (28)

Country Link
US (2) US20060251676A1 (enExample)
EP (1) EP1572233B1 (enExample)
JP (1) JP5475939B2 (enExample)
KR (3) KR101361769B1 (enExample)
AP (1) AP2005003347A0 (enExample)
AR (1) AR042530A1 (enExample)
AT (1) ATE503492T1 (enExample)
AU (1) AU2003293942B2 (enExample)
BE (3) BE2015C068I2 (enExample)
BR (1) BR0317544A (enExample)
CA (1) CA2510457C (enExample)
CY (1) CY1111552T1 (enExample)
DE (1) DE60336581D1 (enExample)
DK (1) DK1572233T3 (enExample)
EA (2) EA009179B1 (enExample)
EC (1) ECSP055869A (enExample)
IL (1) IL169085A (enExample)
IS (1) IS2811B (enExample)
MA (1) MA27581A1 (enExample)
MX (1) MXPA05006764A (enExample)
MY (1) MY144492A (enExample)
NO (1) NO20052846L (enExample)
NZ (1) NZ540811A (enExample)
OA (1) OA13147A (enExample)
PL (1) PL215257B1 (enExample)
PT (1) PT1572233E (enExample)
TW (1) TWI349557B (enExample)
WO (1) WO2004056389A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000087I1 (de) 1998-10-16 2008-03-27 Glaxosmithkline Biolog Sa Adjuvanzsysteme und impfstoffe
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
MXPA06014515A (es) * 2004-06-16 2007-03-23 Glaxosmithkline Biolog Sa Vacuna contra vph16 y vph18 y al menos otro tipo de vph seleccionado de vph 31, 45 o 52.
US7758866B2 (en) * 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
AU2006236905B2 (en) 2005-04-15 2010-06-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
KR20080005585A (ko) * 2005-04-26 2008-01-14 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
KR20080005583A (ko) * 2005-04-26 2008-01-14 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
US9364529B2 (en) 2007-04-29 2016-06-14 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated L1 protein of human papillomavirus type 18
DK2154147T3 (en) 2007-04-29 2015-12-07 Beijing Wantai Biological Pharmacy Entpr Co Ltd Truncated L1 protein of human papillomavirus 16
DK2403507T3 (en) 2009-03-05 2018-06-06 Jenny Colleen Mccloskey TREATMENT OF INFECTION
WO2010147268A1 (ko) 2009-06-19 2010-12-23 아이진 주식회사 자궁경부암 백신
US20170212116A1 (en) 2014-01-31 2017-07-27 Ulisse Biomed Srl Biosensors for the detection of infection and associated maladies
US10799574B2 (en) 2014-10-24 2020-10-13 Hpvvax. Llc Method and composition for treating cancer or skin lesion using a vaccine
EP3209676A4 (en) 2014-10-24 2018-03-28 Hpvvax, Llc Cancer and skin lesion treatment
WO2016194685A1 (ja) * 2015-06-02 2016-12-08 テルモ株式会社 アルミニウムを含有するアジュバント組成物およびこれを含むワクチン組成物
IL277128B2 (en) 2018-03-06 2025-11-01 Precigen Inc Hepatitis b vaccines and uses of the same
JP7581048B2 (ja) 2018-03-06 2024-11-12 プレシゲン，インコーポレイテッド ヒトパピローマウイルスワクチンおよびその使用
CN110551182A (zh) * 2018-06-04 2019-12-10 厦门大学 一种人乳头瘤病毒18型l1蛋白的突变体
SG11202105276TA (en) 2018-12-03 2021-06-29 Univ Texas Oligo-benzamide analogs and their use in cancer treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4332596A1 (de) * 1993-09-24 1995-03-30 Martin Josef Dr Sapp Monoklonale Antikörper
ES2268787T3 (es) 1997-09-05 2007-03-16 Medimmune, Inc. Metodo in vitro de desmontaje/embalaje de particulas similares a virus (vlp) de papilomavirus.
SI1150712T1 (sl) * 1999-02-05 2009-02-28 Merck & Co Inc Pripravek cepiva proti humanem papiloma virusu
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
HRP20021015A2 (en) * 2000-06-26 2004-02-29 Stressgen Biotechnologies Corp Human papilloma virus treatment

Also Published As

Publication number Publication date
IL169085A0 (en) 2007-07-04
HK1085378A1 (en) 2006-08-25
EA009179B1 (ru) 2007-12-28
BE2015C069I2 (enExample) 2024-08-08
CA2510457A1 (en) 2004-07-08
TWI349557B (en) 2011-10-01
KR20120118087A (ko) 2012-10-25
MXPA05006764A (es) 2005-09-08
DK1572233T3 (da) 2011-06-27
EP1572233B1 (en) 2011-03-30
KR20050086924A (ko) 2005-08-30
US20060251676A1 (en) 2006-11-09
AR042530A1 (es) 2005-06-22
CA2510457C (en) 2011-12-06
PL377710A1 (pl) 2006-02-06
AU2003293942A1 (en) 2004-07-14
PL215257B1 (pl) 2013-11-29
CY1111552T1 (el) 2015-08-05
BE2015C067I2 (enExample) 2024-08-08
DE60336581D1 (de) 2011-05-12
ATE503492T1 (de) 2011-04-15
KR101361769B1 (ko) 2014-02-10
OA13147A (en) 2006-12-13
JP5475939B2 (ja) 2014-04-16
US20050287161A1 (en) 2005-12-29
IS2811B (is) 2012-11-15
NZ540811A (en) 2007-03-30
BR0317544A (pt) 2005-11-22
KR20120123616A (ko) 2012-11-08
PT1572233E (pt) 2011-06-07
NO20052846L (no) 2005-07-13
BE2015C068I2 (enExample) 2024-08-08
ECSP055869A (es) 2005-09-20
AP2005003347A0 (en) 2005-06-30
TW200423957A (en) 2004-11-16
IS7885A (is) 2005-06-09
JP2006512413A (ja) 2006-04-13
EP1572233A1 (en) 2005-09-14
MY144492A (en) 2011-09-30
EA200500834A1 (ru) 2006-02-24
WO2004056389A1 (en) 2004-07-08
MA27581A1 (fr) 2005-10-03
AU2003293942B2 (en) 2009-12-10
IL169085A (en) 2014-04-30

Similar Documents

Publication Publication Date Title
EA200701633A1 (ru) Вакцина на основе вирусоподобных частиц вируса папилломы человека 16 и вируса папилломы человека 18 l1
EA200401064A1 (ru) Вирусоподобные частицы из вируса папилломы человека
DE60040727D1 (de) Menschliche papillomavirus impfstoff-formulierungen
EP1246644A4 (en) HUMAN PAPILLOMAVIRUS CELLULAR IMMUNE RESPONSE INDUCED BY USE OF PEPTIDE COMPOSITIONS AND NUCLEIC ACID
DK1292328T3 (da) Kimære humant papillomvirus- (HPV) - molekyler og deres anvendelse
WO2003078455A3 (en) Virus like particle from papillomavirus and their use in vaccine
DE60119734D1 (de) Hpv-e7 zur behandlung von menschlichem papillomavirus
BR9814606A (pt) Formulação de vacina e métodos de tratamento de um indivìduo infectado com um vìrus hpv e de prevenção de infecção por papiloma vìrus
LU91314I2 (fr) "Combinaison de particules viroides de papillomavirus humain de type 6, 11, 16 et 18 (GARDASIL -GilGARD )"
WO2005089164A3 (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
MY134041A (en) Novel composition
JOP20220187A1 (ar) لقاح فيروس الورم الحليمي البشري (hpv)
EP1223976A4 (en) A NEW METHOD FOR THE PRODUCTION OF VIRUS-LIKE PARTICLES OF HUMAN PAPILLOMA VIRUS WITH IMPROVED PROPERTIES
DE60236806D1 (de) Transkutane immunisierung gegen papillomavirus mit virusähnlichen papillomaviruspartikeln
ATE474596T1 (de) Impfstoff gegen humanes papillomavirus zur oralen verabreichung
EP0863982A4 (en) SYNTHETIC HPV11 VIRUS-LIKE PARTICLES
DE60124725D1 (de) Herstellung eines chimeren papillomavirus
SI1572233T1 (sl) Uporaba HPV16 in HPV18 kot cepivo proti enemu ali več onkogenih HPV tipa 31,33,35,39,45,51,52,56,58,59,66,68
WO2002055542A3 (de) Hpv-spezifische peptide, die die bindung von hpv an die wirtszelle blockieren
SE0002498D0 (sv) Papillomavirus vaccine
EA200702077A1 (ru) Вакцина
ATE349532T1 (de) Zytotoxisches t-zellepitop des papillomavirus l1- proteins und seine verwendung in diagnostik und therapie
FR2829506B1 (fr) Nouvelle methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine(hiv)
BR0309603A (pt) Polipeptìdeo e7 mutado de hpv-16, composição farmacêutica que o compreende e seu processo de preparação